B. Riley Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
$227K Buy
384
+62
+19% +$40.3K 0.02% 525
2022
Q1
$225K Buy
+322
New +$204K 0.02% 528
2020
Q3
Sell
-1,075
Closed -$670K 506
2020
Q2
$670K Buy
+1,075
New +$610K 0.07% 198
2015
Q3
Sell
-200
Closed -$102K 615
2015
Q2
$102K Buy
+200
New +$97.6K 0.08% 275

Other funds holding REGN

B. Riley Wealth Management's REGN Position: Q2 2022 in Review

B. Riley Wealth Management increased its Regeneron Pharmaceuticals (REGN) stake by 19% in Q2 2022, buying an estimated $40.3K and bringing the position to 384 shares worth $227K. The position accounts for 0.02% of the portfolio, ranked #525.

B. Riley Wealth Management first reported a position in REGN in Q2 2015 and has held it in 4 quarters since. The position peaked at $670K in Q2 2020. 1,064 funds tracked by Wall St. Rank hold REGN as of Q2 2022.

  • B. Riley Wealth Management held 384 shares of Regeneron Pharmaceuticals worth $227K as of Q2 2022.
  • B. Riley Wealth Management bought 62 Regeneron Pharmaceuticals shares in Q2 2022, an estimated $40.3K.
  • Regeneron Pharmaceuticals made up 0.02% of B. Riley Wealth Management's portfolio in Q2 2022, its #525 holding.
  • B. Riley Wealth Management first reported a position in Regeneron Pharmaceuticals in Q2 2015 and has held it in 4 quarters since.
  • B. Riley Wealth Management's Regeneron Pharmaceuticals position peaked at $670K in Q2 2020.
  • 1,064 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2022.

Based on B. Riley Wealth Management's 13F filing for Q2 2022, filed 9 Sep 2022.